-
公开(公告)号:US20220098680A1
公开(公告)日:2022-03-31
申请号:US17595776
申请日:2020-05-29
申请人: UNIVERSITÉ DE PARIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
IPC分类号: C12Q1/6886
摘要: The invention relates to a method for diagnosing or identifying pancreas cancer in a subject. The inventors indeed identified two DNA methylation biomarkers that, alone, preferably in combination, can help diagnosing or following-up pancreatic cancer patients very specifically, discriminating with other type of cancers. Further, it can be used for determining, adapting a suitable therapeutic regimen for a subject diagnosed for pancreas cancer. The present invention also relates to kit comprising primers or probes to detect, diagnose, identify hypermethylated genes.
-
102.
公开(公告)号:US20220037757A1
公开(公告)日:2022-02-03
申请号:US17312842
申请日:2019-12-04
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , OBSERVATOIRE DE PARIS , CY CERGY PARIS UNIVERSITÉ , SORBONNE UNIVERSITE , UNIVERSITÉ DE PARIS
摘要: A method for manufacturing a superconducting LC-type resonator of the type including at least one high-resistivity substrate on which are printed an inductive meander, a first so-called lower electrode and a second so-called upper electrode arranged opposite the first so as to form together a capacitor connected in parallel with the inductive meander, as well as inductive coupling means dedicated to the resonator, in which a sacrificial aluminium layer is deposited between the first and second electrodes. Also disclosed is the superconducting LC-type resonator thus obtained and the use of such a resonator for detecting the noise of a millimetre photon.
-
公开(公告)号:US11236300B2
公开(公告)日:2022-02-01
申请号:US15770472
申请日:2016-10-21
申请人: Centre National de la Recherche Scientifique (CNRS) , Institut Curie , Sorbonne Universite , Université de Paris
发明人: Catherine Villard , Jean-Louis Viovy , Renaud Renault , Jean-Baptiste Durand , Jean-Michel Peyrin , Ivan Ferrante
摘要: The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.
-
公开(公告)号:US20210393632A1
公开(公告)日:2021-12-23
申请号:US17281745
申请日:2019-10-03
申请人: INSERM (Institut National de la Santé et de la Recherche Médicale) , Assistance Publique-Hôpitaux de Paris (APHP) , Université de Paris , Fondation Imagine , Université Paris-Sud
发明人: Christine BODEMER , Céline GRECO , Claude BOUCHEIX
IPC分类号: A61K31/517 , A61K31/675 , A61K31/5377 , A61K31/519 , A61K31/506 , A61K31/4706 , A61P17/12
摘要: Olmsted syndrome (OS) is a rare genodermatosis classically characterized by the combination of bilateral mutilating transgredient palmoplantar keratoderma (PPK) and periorificial keratotic plaques. The inventors obtained remarkable results with a treatment with a EGFR inhibitor (e.g. erlotinib) in 3 patients with Olmsted Syndrome and erythemalgia linked to different TRPV3 mutations. In less than 3 months, the drug induced a complete disappearance of the hyperkeratosis and the pain. Anorexia and insomnia disappeared with an improvement of the growth. Accordingly, the present invention relates to the use of EGFR inhibitors for the keratodermas.
-
公开(公告)号:US11202826B2
公开(公告)日:2021-12-21
申请号:US16937444
申请日:2020-07-23
摘要: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.
-
公开(公告)号:US20210379146A1
公开(公告)日:2021-12-09
申请号:US17282474
申请日:2019-10-03
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDIGALE) , UNIVERSITÉ DE PARIS , CENTRE NATONAL DE LA RECHERCHE SCIENTFIQUE (CNRS)
发明人: Franck OURY , Patrice CODOGNO
摘要: The present invention relates to the field of memory and cognitive functions. Here the inventors show that memory stimulations induce autophagy in the mouse hippocampus, while local pharmacological and genetic modulations of hippocampal autophagy strongly influence memory acquisition. More, the inventors observe that hippocampal autophagy declines during aging and they find that restoring autophagy specifically in the hippocampus of aged mice, following autophagy inducers (such as TAT-Beclin-1), can significantly reverse age-related memory decline. Their results reveal a novel physiological role of autophagy in regulating hippocampal-dependent memory functions, and demonstrate the potential therapeutic benefits of modulating autophagy in order to prevent and/or reverse the deleterious effects of aging on cognitive function. The present invention relates to an activator of the autophagy for use in the restoration and/or improvement of cognitive functions in a subject in need thereof.
-
公开(公告)号:US20210315831A1
公开(公告)日:2021-10-14
申请号:US17269802
申请日:2019-08-27
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITÉ DE PARIS , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
发明人: Brice MARTIN , Nathalie MIGNET , Yohann CORVIS
IPC分类号: A61K9/51 , A61K31/365 , A61P35/00
摘要: The invention relates to a method for manufacturing a nanostructured powder comprising nanocrystalline agglomerates containing active pharmaceutical ingredient (API) in its crystalline form, said method comprising (i) Preparing a first solution comprising API and an API solvent; (ii) Mixing the first solution with a second solution comprising an API antisolvent and optionally a stabilizing agent P1 to obtain a third mixture; (iii) Evaporating the third mixture until both the API solvent and the API antisolvent are evaporated, advantageously under vacuum; characterized in that when the stabilizing agent P1 is present, the third mixture has a stabilizing agent P to API weight ratio equal or less than 5, preferably less than 2. The invention also concerns a nanostructured powder and a nanosuspension.
-
公开(公告)号:US20210275088A1
公开(公告)日:2021-09-09
申请号:US17253778
申请日:2019-05-27
发明人: Vincent Fleury
摘要: A device for automatically imaging the capillary blood vessels of a living tissue likely to move, configured for selecting images of the sequence, called ‘sharp images’, arranged in chronological order of acquisition, shuffling the sharp images, for decorrelating temporally the sharp images, by arranging them in a shuffled order different from the chronological order, realigning spatially the sharp images arranged in the shuffled order, generating a projected image by projection of the pixels of the realigned sharp images, in a stack, the projected values of the pixels forming the projected image being extremal intensity values of the pixels of all the sharp images, the projection of the extremal of intensity values of the pixels rendering all the positions of all erythrocytes of all the sharp images in the projected image.
-
公开(公告)号:US20210228738A1
公开(公告)日:2021-07-29
申请号:US17050911
申请日:2017-07-17
申请人: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , GENETHON , SORBONNE UNIVERSITÉ , UNIVERSITÉ DE PARIS , SPARK THERAPEUTICS, INC.
发明人: Sébastien LACROIX-DESMAZES , Federico MINGOZZI , Jordan DIMITROV , Christian LEBORGNE , Sean ARMOUR
IPC分类号: A61K48/00 , C12N9/24 , C12N15/86 , G01N33/53 , C12N15/113
摘要: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
-
公开(公告)号:US20210169934A1
公开(公告)日:2021-06-10
申请号:US17173632
申请日:2021-02-11
申请人: Assistance Publique - Hopitaux de Paris , Fondation Imagine - Institut des Maladies Génétiques , Université de Paris , Institut National de la Santé et de la Recherche Médicale (INSERM)
发明人: Isabelle André , Marina Cavazzana , Kuiying Ma , John Tchen
IPC分类号: A61K35/17 , C12N5/0783
摘要: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
-
-
-
-
-
-
-
-
-